Marie Riis Mortensen, Tue Duy Ngyuen, Hans Henrik Madsen, Michelle Meier
{"title":"永久性腹膜胸膜导尿管作为恶性腹水姑息性治疗的建立。","authors":"Marie Riis Mortensen, Tue Duy Ngyuen, Hans Henrik Madsen, Michelle Meier","doi":"10.61409/A02240098","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Refractory malignant ascites (RMA) is a manifestation of end-stage cancer disease with a major impact on quality of life due to the symptom burden and need for repeated hospitalisations. We previously described the implantation of the permanent PleurX catheter as a treatment of RMA. The present study aimed to evaluate and describe our experience with the permanent PleurX catheter system in the largest cohort to date.</p><p><strong>Methods: </strong>A total of 97 consecutive patients had a PleurX catheter implanted from 2015 to 2021. We retrieved retrospective data on patients and procedures using the patient's medical records.</p><p><strong>Results: </strong>A total of 96 (99%) of implantations were successful, and all patients had symptom relief. Six patients (6%) experienced minor or moderate adverse events: three due to infection, two due to leakage and one because of hypotension. The mean residual lifetime was 77 days.</p><p><strong>Conclusions: </strong>We established that implantation of the permanent peritoneal PleurX catheter is a safe and efficient treatment of RMA. We emphasise the importance of early detection and intervention in the management of RMA by implantation of a permanent peritoneal catheter.</p><p><strong>Funding: </strong>None.</p><p><strong>Trial registration: </strong>Not relevant.</p>","PeriodicalId":11119,"journal":{"name":"Danish medical journal","volume":"71 12","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Establishment of permanent peritoneal PleurX catheter as palliative treatment of malignant ascites.\",\"authors\":\"Marie Riis Mortensen, Tue Duy Ngyuen, Hans Henrik Madsen, Michelle Meier\",\"doi\":\"10.61409/A02240098\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Refractory malignant ascites (RMA) is a manifestation of end-stage cancer disease with a major impact on quality of life due to the symptom burden and need for repeated hospitalisations. We previously described the implantation of the permanent PleurX catheter as a treatment of RMA. The present study aimed to evaluate and describe our experience with the permanent PleurX catheter system in the largest cohort to date.</p><p><strong>Methods: </strong>A total of 97 consecutive patients had a PleurX catheter implanted from 2015 to 2021. We retrieved retrospective data on patients and procedures using the patient's medical records.</p><p><strong>Results: </strong>A total of 96 (99%) of implantations were successful, and all patients had symptom relief. Six patients (6%) experienced minor or moderate adverse events: three due to infection, two due to leakage and one because of hypotension. The mean residual lifetime was 77 days.</p><p><strong>Conclusions: </strong>We established that implantation of the permanent peritoneal PleurX catheter is a safe and efficient treatment of RMA. We emphasise the importance of early detection and intervention in the management of RMA by implantation of a permanent peritoneal catheter.</p><p><strong>Funding: </strong>None.</p><p><strong>Trial registration: </strong>Not relevant.</p>\",\"PeriodicalId\":11119,\"journal\":{\"name\":\"Danish medical journal\",\"volume\":\"71 12\",\"pages\":\"\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-11-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Danish medical journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.61409/A02240098\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Danish medical journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.61409/A02240098","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Establishment of permanent peritoneal PleurX catheter as palliative treatment of malignant ascites.
Introduction: Refractory malignant ascites (RMA) is a manifestation of end-stage cancer disease with a major impact on quality of life due to the symptom burden and need for repeated hospitalisations. We previously described the implantation of the permanent PleurX catheter as a treatment of RMA. The present study aimed to evaluate and describe our experience with the permanent PleurX catheter system in the largest cohort to date.
Methods: A total of 97 consecutive patients had a PleurX catheter implanted from 2015 to 2021. We retrieved retrospective data on patients and procedures using the patient's medical records.
Results: A total of 96 (99%) of implantations were successful, and all patients had symptom relief. Six patients (6%) experienced minor or moderate adverse events: three due to infection, two due to leakage and one because of hypotension. The mean residual lifetime was 77 days.
Conclusions: We established that implantation of the permanent peritoneal PleurX catheter is a safe and efficient treatment of RMA. We emphasise the importance of early detection and intervention in the management of RMA by implantation of a permanent peritoneal catheter.
期刊介绍：
The Danish Medical Journal (DMJ) is a general medical journal. The journal publish original research in English – conducted in or in relation to the Danish health-care system. When writing for the Danish Medical Journal please remember target audience which is the general reader. This means that the research area should be relevant to many readers and the paper should be presented in a way that most readers will understand the content.
DMJ will publish the following articles:
• Original articles
• Protocol articles from large randomized clinical trials
• Systematic reviews and meta-analyses
• PhD theses from Danish faculties of health sciences
• DMSc theses from Danish faculties of health sciences.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
